The invention provides methods of treatment or prophylaxis of obesity, or methods of treatment for the reduction of food intake, comprising administering to a patient in need of such treatment a therapeutically effective amount of a sulfonamide compound of Formula I:
1
wherein the substituents are as described in the specification.
本发明提供了治疗或预防肥胖症的方法,或减少食物摄入量的治疗方法,包括向需要这种治疗的患者施用治疗有效量的式 I 的磺酰胺化合物:
1
其中取代基如说明书所述。
ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY
申请人:SmithKline Beecham plc
公开号:EP1228043B1
公开(公告)日:2005-01-12
SULFONAMIDE DERIVATIVES
申请人:SMITHKLINE BEECHAM PLC
公开号:EP1228066A2
公开(公告)日:2002-08-07
USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE
申请人:Biovitrum AB (publ)
公开号:EP1450806B1
公开(公告)日:2009-04-29
[EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
申请人:SMITHKLINE BEECHAM PLC
公开号:WO2001032646A2
公开(公告)日:2001-05-10
Novel sulfonamide compounds having CNS activity, processes for their preparation, to compositions containing the same and their use as medicaments.